Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (+)-schisandrin B | multiple interactions | EXP | | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of RPL22L1 mRNA] | CTD | PMID:31150632 | (1->4)-beta-D-glucan | multiple interactions | ISO | Rpl22l1 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of RPL22L1 mRNA | CTD | PMID:36331819 | 1,1-dichloroethene | increases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | vinylidene chloride results in increased expression of RPL22L1 mRNA | CTD | PMID:26682919 | 1,2-dimethylhydrazine | multiple interactions | ISO | Rpl22l1 (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of RPL22L1 mRNA | CTD | PMID:22206623 | 17alpha-ethynylestradiol | affects expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Ethinyl Estradiol affects the expression of RPL22L1 mRNA | CTD | PMID:17555576 | 17beta-estradiol | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Estradiol results in decreased expression of RPL22L1 mRNA | CTD | PMID:23019147 | 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of RPL22L1 mRNA | CTD | PMID:32145629 | 2,2',4,4'-Tetrabromodiphenyl ether | affects expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | 2 more ... | CTD | PMID:30294300 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of RPL22L1 mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of RPL22L1 mRNA | CTD | PMID:34747641 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of RPL22L1 mRNA | CTD | PMID:15328365 | 2,3,7,8-Tetrachlorodibenzofuran | increases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:32109520 | 2-hydroxypropanoic acid | affects expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Lactic Acid affects the expression of RPL22L1 mRNA | CTD | PMID:30851411 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RPL22L1 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of RPL22L1 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of RPL22L1 mRNA | CTD | PMID:28628672 | 4,4'-sulfonyldiphenol | multiple interactions | ISO | RPL22L1 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of RPL22L1 mRNA | CTD | PMID:28628672 | 4-hydroxyphenyl retinamide | decreases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Fenretinide results in decreased expression of RPL22L1 mRNA | CTD | PMID:28973697 | acrylamide | increases expression | EXP | | 6480464 | Acrylamide results in increased expression of RPL22L1 mRNA | CTD | PMID:28959563 | aflatoxin B1 | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased expression of RPL22L1 mRNA | CTD | PMID:22100608 | aflatoxin B1 | decreases expression | EXP | | 6480464 | Aflatoxin B1 results in decreased expression of RPL22L1 mRNA | CTD | PMID:22484513 and PMID:23630614 | aflatoxin B1 | decreases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Aflatoxin B1 results in decreased expression of RPL22L1 mRNA | CTD | PMID:19770486 | antirheumatic drug | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Antirheumatic Agents results in decreased expression of RPL22L1 mRNA | CTD | PMID:24449571 | Aroclor 1254 | increases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Chlorodiphenyl (54% Chlorine) results in increased expression of RPL22L1 mRNA | CTD | PMID:23650126 | arsenite(3-) | multiple interactions | ISO | RPL22L1 (Homo sapiens) | 6480464 | arsenite promotes the reaction [G3BP1 protein binds to RPL22L1 mRNA] | CTD | PMID:32406909 | benzo[a]pyrene | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased expression of RPL22L1 mRNA | CTD | PMID:20106945 and PMID:21632981 | benzo[a]pyrene | increases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of RPL22L1 mRNA | CTD | PMID:22228805 | benzo[a]pyrene | decreases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased expression of RPL22L1 mRNA | CTD | PMID:19770486 more ... | benzo[a]pyrene | multiple interactions | ISO | Rpl22l1 (Mus musculus) | 6480464 | AHR protein affects the reaction [Benzo(a)pyrene affects the expression of RPL22L1 mRNA] | CTD | PMID:22228805 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | 7 more ... | CTD | PMID:26238291 | bis(2-ethylhexyl) phthalate | decreases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Diethylhexyl Phthalate results in decreased expression of RPL22L1 mRNA | CTD | PMID:19850644 | bis(2-ethylhexyl) phthalate | multiple interactions | ISO | Rpl22l1 (Mus musculus) | 6480464 | PPARA protein inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of RPL22L1 mRNA] | CTD | PMID:19850644 | bisphenol A | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with Testosterone] results in increased expression of RPL22L1 mRNA | CTD | PMID:26496021 | bisphenol A | increases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | bisphenol A results in increased expression of RPL22L1 mRNA | CTD | PMID:32156529 more ... | bisphenol A | affects expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | bisphenol A affects the expression of RPL22L1 mRNA | CTD | PMID:30903817 | bisphenol A | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | bisphenol A results in decreased expression of RPL22L1 mRNA and bisphenol A results in decreased expression of RPL22L1 protein | CTD | PMID:29275510 more ... | bisphenol A | multiple interactions | ISO | RPL22L1 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of RPL22L1 mRNA | CTD | PMID:28628672 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of RPL22L1 mRNA | CTD | PMID:25181051 and PMID:32145629 | cadmium atom | multiple interactions | ISO | RPL22L1 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of RPL22L1 mRNA | CTD | PMID:35301059 | cadmium dichloride | multiple interactions | ISO | RPL22L1 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of RPL22L1 mRNA | CTD | PMID:35301059 | casticin | decreases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | casticin results in decreased expression of RPL22L1 mRNA | CTD | PMID:28444820 | chromium(6+) | affects expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | chromium hexavalent ion affects the expression of RPL22L1 mRNA | CTD | PMID:28472532 | clofibric acid | affects expression | EXP | | 6480464 | Clofibric Acid affects the expression of RPL22L1 mRNA | CTD | PMID:17602206 | copper atom | decreases expression | EXP | | 6480464 | Copper results in decreased expression of RPL22L1 mRNA | CTD | PMID:30556269 | copper(0) | decreases expression | EXP | | 6480464 | Copper results in decreased expression of RPL22L1 mRNA | CTD | PMID:30556269 | crocidolite asbestos | increases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Asbestos and Crocidolite results in increased expression of RPL22L1 mRNA | CTD | PMID:29279043 | cyclosporin A | increases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Cyclosporine results in increased expression of RPL22L1 mRNA | CTD | PMID:25562108 | deoxynivalenol | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | deoxynivalenol results in decreased expression of RPL22L1 mRNA | CTD | PMID:31863870 | dexamethasone | multiple interactions | ISO | RPL22L1 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of RPL22L1 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of RPL22L1 mRNA | CTD | PMID:28628672 | dicrotophos | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | dicrotophos results in decreased expression of RPL22L1 mRNA | CTD | PMID:28302478 | disodium selenite | increases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Sodium Selenite results in increased expression of RPL22L1 mRNA | CTD | PMID:18175754 | dorsomorphin | multiple interactions | ISO | RPL22L1 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | entinostat | increases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | entinostat results in increased expression of RPL22L1 mRNA | CTD | PMID:26272509 | entinostat | multiple interactions | ISO | RPL22L1 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPL22L1 mRNA | CTD | PMID:27188386 | epoxiconazole | increases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | epoxiconazole results in increased expression of RPL22L1 mRNA | CTD | PMID:35436446 | ethanol | increases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Ethanol results in increased expression of RPL22L1 mRNA | CTD | PMID:30319688 | flutamide | increases expression | EXP | | 6480464 | Flutamide results in increased expression of RPL22L1 mRNA | CTD | PMID:24136188 | folic acid | multiple interactions | ISO | Rpl22l1 (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of RPL22L1 mRNA | CTD | PMID:22206623 | formaldehyde | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Formaldehyde results in decreased expression of RPL22L1 mRNA | CTD | PMID:23649840 | FR900359 | increases phosphorylation | ISO | RPL22L1 (Homo sapiens) | 6480464 | FR900359 results in increased phosphorylation of RPL22L1 protein | CTD | PMID:37730182 | genistein | decreases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Genistein results in decreased expression of RPL22L1 mRNA | CTD | PMID:32186404 | gentamycin | decreases expression | EXP | | 6480464 | Gentamicins results in decreased expression of RPL22L1 mRNA | CTD | PMID:33387578 | glafenine | increases expression | EXP | | 6480464 | Glafenine results in increased expression of RPL22L1 mRNA | CTD | PMID:24136188 | hydrogen peroxide | affects expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Hydrogen Peroxide affects the expression of RPL22L1 mRNA | CTD | PMID:20044591 | hydroxyurea | decreases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Hydroxyurea results in decreased expression of RPL22L1 mRNA | CTD | PMID:12929121 | indole-3-methanol | affects expression | EXP | | 6480464 | indole-3-carbinol affects the expression of RPL22L1 mRNA | CTD | PMID:21396975 | indometacin | multiple interactions | ISO | RPL22L1 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of RPL22L1 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of RPL22L1 mRNA | CTD | PMID:28628672 | ivermectin | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Ivermectin results in decreased expression of RPL22L1 protein | CTD | PMID:32959892 | lead diacetate | decreases expression | EXP | | 6480464 | lead acetate results in decreased expression of RPL22L1 mRNA | CTD | PMID:22641619 | methyl methanesulfonate | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Methyl Methanesulfonate results in decreased expression of RPL22L1 mRNA | CTD | PMID:23649840 | nefazodone | increases expression | EXP | | 6480464 | nefazodone results in increased expression of RPL22L1 mRNA | CTD | PMID:24136188 | nimesulide | increases expression | EXP | | 6480464 | nimesulide results in increased expression of RPL22L1 mRNA | CTD | PMID:24136188 | nitrofen | increases expression | EXP | | 6480464 | nitrofen results in increased expression of RPL22L1 mRNA | CTD | PMID:33484710 | ozone | multiple interactions | ISO | Rpl22l1 (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of RPL22L1 mRNA | CTD | PMID:34911549 | ozone | multiple interactions | ISO | RPL22L1 (Homo sapiens) | 6480464 | [Air Pollutants results in increased abundance of Ozone] which affects the expression of RPL22L1 mRNA | CTD | PMID:35430440 | p-anisidine | decreases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | 4-anisidine results in decreased expression of RPL22L1 mRNA | CTD | PMID:12929121 | paclitaxel | decreases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Paclitaxel results in decreased expression of RPL22L1 mRNA | CTD | PMID:12929121 | paracetamol | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Acetaminophen results in decreased expression of RPL22L1 mRNA | CTD | PMID:22230336 | paracetamol | affects expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Acetaminophen affects the expression of RPL22L1 mRNA | CTD | PMID:17562736 | paracetamol | increases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Acetaminophen results in increased expression of RPL22L1 mRNA | CTD | PMID:21420995 | perfluorononanoic acid | increases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | perfluoro-n-nonanoic acid results in increased expression of RPL22L1 mRNA | CTD | PMID:32588087 | perfluorooctane-1-sulfonic acid | decreases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | perfluorooctane sulfonic acid results in decreased expression of RPL22L1 protein | CTD | PMID:26178269 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Rpl22l1 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of RPL22L1 mRNA | CTD | PMID:36331819 | progesterone | increases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Progesterone results in increased expression of RPL22L1 mRNA | CTD | PMID:21540246 | propiconazole | increases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | propiconazole results in increased expression of RPL22L1 mRNA | CTD | PMID:21278054 | rac-lactic acid | affects expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Lactic Acid affects the expression of RPL22L1 mRNA | CTD | PMID:30851411 | SB 431542 | multiple interactions | ISO | RPL22L1 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | silicon dioxide | increases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Silicon Dioxide analog results in increased expression of RPL22L1 mRNA | CTD | PMID:25895662 | sodium arsenite | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | sodium arsenite results in decreased expression of RPL22L1 mRNA and sodium arsenite results in decreased expression of RPL22L1 protein | CTD | PMID:30528433 and PMID:34032870 | sodium dodecyl sulfate | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Sodium Dodecyl Sulfate results in decreased expression of RPL22L1 mRNA | CTD | PMID:31734321 | tamoxifen | affects expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Tamoxifen affects the expression of RPL22L1 mRNA | CTD | PMID:17555576 | testosterone | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with Testosterone] results in increased expression of RPL22L1 mRNA | CTD | PMID:26496021 | tetrachloroethene | increases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Tetrachloroethylene results in increased expression of RPL22L1 mRNA | CTD | PMID:28973375 | tetrachloromethane | affects expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Carbon Tetrachloride affects the expression of RPL22L1 mRNA | CTD | PMID:17484886 | tetrachloromethane | multiple interactions | EXP | | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of RPL22L1 mRNA] | CTD | PMID:31150632 | tetrachloromethane | increases expression | EXP | | 6480464 | Carbon Tetrachloride results in increased expression of RPL22L1 mRNA | CTD | PMID:31150632 | thioacetamide | increases expression | EXP | | 6480464 | Thioacetamide results in increased expression of RPL22L1 mRNA | CTD | PMID:34492290 | tolcapone | decreases expression | EXP | | 6480464 | tolcapone results in decreased expression of RPL22L1 mRNA | CTD | PMID:24136188 | trichostatin A | increases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | trichostatin A results in increased expression of RPL22L1 mRNA | CTD | PMID:24935251 and PMID:26272509 | trichostatin A | multiple interactions | ISO | RPL22L1 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPL22L1 mRNA | CTD | PMID:27188386 | tris(2-butoxyethyl) phosphate | increases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | tris(2-butoxyethyl) phosphate results in increased expression of RPL22L1 mRNA | CTD | PMID:29024780 | tungsten | increases expression | ISO | Rpl22l1 (Mus musculus) | 6480464 | Tungsten results in increased expression of RPL22L1 mRNA | CTD | PMID:30912803 | valproic acid | affects expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Valproic Acid affects the expression of RPL22L1 mRNA | CTD | PMID:25979313 | valproic acid | multiple interactions | ISO | RPL22L1 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPL22L1 mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of RPL22L1 mRNA | CTD | PMID:27188386 and PMID:29154799 | valproic acid | increases expression | ISO | RPL22L1 (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of RPL22L1 mRNA | CTD | PMID:23179753 and PMID:26272509 | vinclozolin | decreases expression | EXP | | 6480464 | vinclozolin results in decreased expression of RPL22L1 mRNA | CTD | PMID:22615374 and PMID:23034163 | |